Boehringer Ingelheim will share patient level clinical study data with broad scientific community
“We are delighted to include Boehringer Ingelheim studies on the Vivli platform,” said Rebecca Li, Vivli Executive Director. “Leaders such as Boehringer Ingelheim are joining platforms such as Vivli to drive scientific discovery through data sharing to advance human health.”
Boehringer Ingelheim is a global, research-driven pharmaceutical company embracing many cultures and diverse societies. In joining Vivli, Boehringer Ingelheim demonstrates their strong commitment to clinical trial data sharing, to promote transparency and drive new discoveries. Boehringer Ingelheim supports Vivli’s mission, which is to promote, coordinate, and facilitate scientific sharing and reuse of clinical research data through the implementation of a sustainable global data-sharing enterprise.
“Pharmaceutical companies like us generate year by year a wealth of clinical drug development data which – after regulatory submission and evaluation – represent an invaluable asset for independent researchers to improve various public health aspects. Technology nowadays allows easy sharing of such huge data streams and Boehringer Ingelheim would like to contribute to the expansion of this knowledge by providing our own data, which has been created by our more than 7000 employees in R+D worldwide and the health care personnel and patients we work with,” says Hans-Juergen Lomp, Head of Global Statistics.
About Boehringer Ingelheim
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company, therefore, concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.
Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company, therefore, aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.